JenniferLHolter-ChakrabartyMD

Physician

Dr. Holter-Chakrabarty is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
825 NE 10th St
Oupb 5200
Oklahoma City, OK 73104
Phone+1 405-271-8299

University of Oklahoma Health Sciences CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
University of Oklahoma Health Sciences CenterResidency, Internal Medicine, 1999 - 2002
University of Oklahoma College of MedicineClass of 1999

PubMed

135 citations
Efficacy of transfusion with granulocytes from G-CSF/dexamethasone–treated donors in neutropenic patients with infection
Thomas H. Price, Michael Boeckh, Ryan W. Harrison, Jeffrey McCullough, Paul M. Ness
Blood. 2015-10-29
141 citations
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Marcela V. Maus, Sara Alexander, Michael R. Bishop, Jennifer N. Brudno, Colleen Callahan
Journal for Immunotherapy of Cancer. 2020-12-01
14 citations
SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis.
Guru Prasad Maiti, Sutapa Sinha, Hasan Mahmud, Justin C. Boysen, Mariana T. Mendez
Blood Cancer Journal. 2021-05-17

Abstracts/Posters

Hypomethylating Agent Maintenance Therapy after Allogeneic Stem Cell Transplant Improves Transplant Outcome in High Risk Acute Myelogenous Leukemia
Jennifer Holter Chakrabarty, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

The Leukemia & Lymphoma Society (LLS) and the American Society of Hematology (ASH) Team up to Connect Blood Cancer Patients to Clinical Trials That Can Lead to New and Better TreatmentsDecember 6th, 2019
Calculating the Costs of Clinical TrialsDecember 1st, 2019